PriceTargets.com logo

OTCMKTS:CURLF - Curaleaf Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.50
  • Forecasted Upside: 62.57 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$13.84 As of 04/16/2021 01:00 AM ET
▼ -0.16 (-1.14%)
1 month | 3 months | 12 months
Get New Curaleaf Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CURLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CURLF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.50
▲ +62.57% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Curaleaf in the last 3 months. The average price target is $22.50, with a high forecast of $32.25 and a low forecast of $16.00. The average price target represents a 62.57% upside from the last price of $13.84.
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Curaleaf. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/17/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/16/2021Needham & Company LLCBoost Price TargetBuy$18.50 ➝ $19.75
i
3/16/2021Cantor FitzgeraldBoost Price TargetOverweight$23.50 ➝ $26.50
i
3/11/2021Canaccord GenuityBoost Price TargetBuy$23.50 ➝ $24.00
i
3/10/2021Cantor FitzgeraldBoost Price TargetOverweight$23.50 ➝ $26.50
i
3/10/2021Needham & Company LLCBoost Price TargetBuy$18.50 ➝ $19.75
i
3/8/2021BTIG ResearchInitiated CoverageBuy
i
2/25/2021Stifel NicolausBoost Price TargetBuy$23.00 ➝ $32.25
i
2/5/2021DA DavidsonReiterated RatingSell
i
1/26/2021Canaccord GenuityBoost Price TargetBuy$29.00
i
1/20/2021Roth CapitalBoost Price TargetBuy$14.00 ➝ $20.00
i
1/20/2021Cantor FitzgeraldBoost Price TargetOverweight$20.00 ➝ $23.50
i
Rating by Pablo Zuanic at Cantor Fitzgerald
1/19/2021Needham & Company LLCBoost Price TargetBuy$14.00 ➝ $18.50
i
Rating by Matt McGinley at Needham & Company LLC
1/13/2021Canaccord GenuityBoost Price TargetBuy$18.50 ➝ $23.50
i
12/3/2020Craig HallumInitiated CoverageBuy$19.00
i
11/18/2020Canaccord GenuityBoost Price TargetBuy$16.00 ➝ $18.50
i
11/18/2020Needham & Company LLCBoost Price TargetBuy$13.50 ➝ $14.00
i
Rating by Matt McGinley at Needham & Company LLC
11/18/2020Cantor FitzgeraldBoost Price TargetOverweight$18.00 ➝ $20.00
i
Rating by Pablo Zuanic at Cantor Fitzgerald
8/18/2020Canaccord GenuityBoost Price TargetBuy$15.00 ➝ $16.00
i
8/18/2020Alliance Global PartnersBoost Price TargetBuy$14.00 ➝ $16.00
i
8/18/2020Needham & Company LLCBoost Price TargetBuy$11.00 ➝ $13.50
i
Rating by Matt McGinley at Needham & Company LLC
8/18/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$18.00
i
Rating by Pablo Zuanic at Cantor Fitzgerald
8/6/2020Needham & Company LLCBoost Price TargetBuy$10.70 ➝ $11.00
i
Rating by Matt McGinley at Needham & Company LLC
8/4/2020Cantor FitzgeraldBoost Price TargetNeutral$7.50 ➝ $10.00
i
Rating by Pablo Zuanic at Cantor Fitzgerald
7/23/2020Alliance Global PartnersBoost Price TargetBuy$12.00 ➝ $14.00
i
7/22/2020Stifel NicolausInitiated CoverageBuy
i
6/22/2020Needham & Company LLCReiterated RatingBuy$10.70
i
6/8/2020Roth CapitalInitiated CoverageBuy$9.00
i
5/19/2020Cantor FitzgeraldBoost Price TargetNeutral$6.00 ➝ $7.50
i
Rating by Pablo Zuanic at Cantor Fitzgerald
5/19/2020Needham & Company LLCBoost Price TargetBuy$5.90 ➝ $10.10
i
5/19/2020Canaccord GenuityReiterated RatingBuy$15.00
i
5/12/2020Needham & Company LLCBoost Price TargetBuy$5.50 ➝ $5.90
i
3/25/2020Cantor FitzgeraldBoost Price TargetNeutral$4.10 ➝ $4.70
i
Rating by Pablo Zuanic at Cantor Fitzgerald
3/17/2020Needham & Company LLCLower Price TargetBuy$8.80 ➝ $5.50
i
2/13/2020Cantor FitzgeraldInitiated CoverageNeutral$8.60
i
2/11/2020Alliance Global PartnersInitiated CoverageBuy
i
12/23/2019Needham & Company LLCReiterated RatingBuy$7.25
i
12/3/2019Needham & Company LLCInitiated CoverageBuy$7.25
i
11/6/2019MKM PartnersUpgradeSell ➝ Neutral
i
9/20/2019MKM PartnersInitiated CoverageSell$5.00
i
9/13/2019CowenInitiated CoverageOutperform$11.00
i
6/10/2019Compass PointInitiated CoverageBuy
i
2/21/2019Seaport Global SecuritiesInitiated CoverageBuy
i
(Data available from 4/17/2016 forward)
Curaleaf logo
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oils for vaporizing, cartridges, tinctures, capsules, and ground-flower. The company also provides hemp-based CBD products. As of March 9, 2021, it operated 101 dispensaries, 23 cultivation sites, and 30 processing sites in 23 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.
Read More

Today's Range

Now: $13.84
$13.45
$14.01

50 Day Range

MA: $15.40
$14.00
$17.01

52 Week Range

Now: $13.84
$3.60
$18.38

Volume

969,501 shs

Average Volume

1,416,510 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Curaleaf?

The following equities research analysts have issued research reports on Curaleaf in the last year: Alliance Global Partners, BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Craig Hallum, DA Davidson, Needham & Company LLC, Roth Capital, and Stifel Nicolaus.
View the latest analyst ratings for CURLF.

What is the current price target for Curaleaf?

7 Wall Street analysts have set twelve-month price targets for Curaleaf in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 62.6%. Stifel Nicolaus has the highest price target set, predicting CURLF will reach $32.25 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $16.00 for Curaleaf in the next year.
View the latest price targets for CURLF.

What is the current consensus analyst rating for Curaleaf?

Curaleaf currently has 1 sell rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CURLF will outperform the market and that investors should add to their positions of Curaleaf.
View the latest ratings for CURLF.

What other companies compete with Curaleaf?

Other companies that are similar to Curaleaf include (THCX.V), 31444, 438280, 815446, Abacus Health Products, Acreage, Althea Group, Applied Biosciences, AusCann Group, Ayr Strategies, Bio-Rad Laboratories, Blueberries Medical, Can B, Cannara Biotech and CannPal Animal Therapeutics.

How do I contact Curaleaf's investor relations team?

The company's listed phone number is 781-451-0150. The official website for Curaleaf is www.curaleaf.com.